(IGXT)Mcap 28 M// Partnership THIS MONTH/1x Approved drug
THIS UNKNOWN GEM IS THE CHEAPEST STOCK WITH THE HIGHEST UPSIDE POTENTIAL IN THE COMPLETE BIOTECH SECTOR .DO YOUR OWN DD AND REALIZE THE MEGA MONSTER POTENTIAL ! GLTA
This Goldmine has a VERY LOW burn-rate of only $1.2 M a year means we have enuff cash untill 2014 EXCLUDING cpi-300 revenue and EXCLUDING upfront payments from upcoming partnerships BUT MORE IMPORTANT TO KNOW IS THAT WE WILL REACH PROFITABILITY THIS YEAR !!!
2x NDA filings for Migraine and Antipsychotic drugs this year which have much bigger market potential than current approved drug .
IGXT has NO DEBT and the Market cap of only 28 M is more than RIDICULOUS for this GOLDMINE .
2 Partnerships coming within 40 days + Profitability this year = TOP PICK 2012
http://www.intelgenx.com/_assets/pdf...-FactSheet.pdf
• Q1,2012
Finalize licensing agreement for CPI‐300
• Q1,2012
Execute definiNve agreement for new Animal Health development and licensing VersaFilm project
• Q2/3,
2012 Commercial launch of CPI*‐300
• Q2,
IntelGenx (IGXT) Submits New Drug Application for Anti-Migraine VersaFilm(TM)
SAINT LAURENT, Quebec, March 27, 2013 (GLOBE NEWSWIRE) -- IntelGenx Corp. (IGX.V) (IGXT) ("IntelGenx" or the "Company"), a Canadian drug delivery company focusing on oral drug delivery, today announced that, together with its co-development partner RedHill Biopharma ("RedHill"), it has submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for the Company's anti-migraine oral film product, a novel oral thin-film formulation based on its proprietary VersaFilm(TM) technology containing Rizatriptan, the active drug in Merck's Maxalt-MLT(R) orally disintegrating tablets.
The company had previously announced a successful a pre-NDA meeting with the FDA following the successful completion of a bioequivalency study demonstrating that its oral film product is bioequivalent with Maxalt MLT(R), a leading branded anti-migraine product manufactured by Merck & Co. According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012. The thin-film formulation of Rizatriptan has been developed in accordance with the co-development and commercialisation agreement with RedHill Biopharma Ltd. (RDHL) (RDHL) using IntelGenx' proprietary immediate release "VersaFilm(TM)" drug delivery technology.
IntelGenx' orally disintegrating film consists of a thin (30 -- 50 um) polymeric film which disintegrates rapidly upon oral administration, thereby releasing the active drug Rizatriptan and making it available for rapid absorption. The film does not require water for administration.